Effectiveness Of Psychedelic Therapy for Post Traumatic Stress Disorder (PTSD)

This interventional trial (n=30) will assess the efficacy and safety of Psychedelic Therapy for Post Traumatic Stress Disorder (PTSD) using MDMA.

Participants will receive MDMA medicines orally in capsule form once in the morning on specific medicine days, alongside psychotherapy sessions. The treatment regimen involves three preparatory sessions, a dosing session lasting approximately 6-7 hours, and three integration sessions, all conducted over several weeks. The therapy sessions will be led by HREC approved psychologists/psychotherapists and a psychiatrist.

The study aims to evaluate changes in clinician-rated PTSD symptoms, trauma, adverse events, personality disorder symptoms, disability, connection, relationships, mystical experiences, alcohol use, drug use, suicidal ideation, depression, eating attitudes, disordered eating, and eating disorder symptomology from baseline to 2 weeks post-treatment.

The trial is recruiting participants in New South Wales, Australia, with a target of 30 participants. It is funded by self-funding and is led by Prof Dr Ranil Gunewardene. For further information, individuals can contact Dr Ranil Gunewardene at Mindlife Clinic Northern Beaches Hospital.

Topic PTSD
Compound MDMA
Country Australia
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.